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BACKGROUND: People living with HIV (PLWH) are at an increased risk of developing several cancers, but to the authors’ knowledge 
less is known regarding how HIV impacts the rate of progression to advanced cancer or death. METHODS: The authors compared 
stage of disease at the time of presentation and mortality after diagnosis between 14,453 PLWH and 6,368,126 HIV-uninfected  
patients diagnosed with cancers of the oral cavity, stomach, colorectum, anus, liver, pancreas, lung, female breast, cervix, pros-
tate, bladder, kidney, and thyroid and melanoma using data from the National Cancer Data Base (2004-2014). Polytomous logistic  
regression and Cox proportional hazards regression were used to evaluate the association between HIV, cancer stage, and stage-
adjusted mortality after diagnosis, respectively. Regression models accounted for the type of health facility at which cancer treat-
ment was administered and the type of individual health insurance. RESULTS: HIV-infected patients with cancer were found to be 
more likely to be uninsured (HIV-infected: 5.0% vs HIV-uninfected: 3.3%; P < .0001) and were less likely to have private health insur-
ance (25.4% vs 44.7%; P < .0001). Compared with those not infected with HIV, the odds of being diagnosed at an advanced stage of 
disease were significantly elevated in PLWH for melanoma and cancers of the oral cavity, liver, female breast, prostate, and thyroid 
(odds ratio for stage IV vs stage I range, 1.24-2.06). PLWH who were diagnosed with stage I to stage III disease experienced elevated 
mortality after diagnosis across 13 of the 14 cancer sites evaluated, with hazard ratios ranging from 1.20 (95% CI, 1.14-1.26) for lung 
cancer to 1.85 (95% CI, 1.68-2.04), 1.85 (95% CI, 1.51-2.27), and 2.93 (95% CI, 2.08-4.13), respectively, for cancers of the female 
breast, cervix, and thyroid. CONCLUSIONS: PLWH were more likely to be diagnosed with advanced-stage cancers and to experience  
elevated mortality after a cancer diagnosis, even after accounting for health care–related factors. Cancer 2019;125:2868-2876.  
© 2019 American Cancer Society. 
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INTRODUCTION
People living with HIV (PLWH) have an elevated risk of certain cancer types, particularly those caused by viral coin-
fections.1-9 Rates of many infection-associated cancers among PLWH have declined after the widespread availability of 
highly active antiretroviral therapy (HAART) to restore patient immunity, although the risk remains elevated compared 
with HIV-uninfected individuals.10-13 Unlike infection-associated cancers, some non–infection-related cancers such as 
those of the prostate, female breast, and colon do not occur at elevated rates in PLWH.14 Nevertheless, these cancers are 
becoming increasingly prevalent among PLWH because of the widespread dissemination of HAART, which permits 
patients with HIV to live to older ages when cancers are more common.15,16 This raises the important question of 
whether HIV-related immunosuppression is associated with tumors progressing to higher stages before being diagnosed 
or resulting in poorer outcomes after diagnosis.
Both advanced stage of disease at the time of presentation and elevated mortality after diagnosis can 
ref lect tumor aggressiveness, and recent data have suggested that immunosuppressed patients fare worse on both 
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metrics. A prior registry-based study demonstrated 
that PLWH were more likely to be diagnosed with 
distant-stage cancers of the lung, female breast, pros-
tate, and bladder and melanoma.17 Stage-adjusted 
mortality after a cancer diagnosis also was elevated 
in HIV-infected patients across a range of sites, in-
cluding cancers of the colorectum, pancreas, larynx, 
lung, female breast, and prostate, and melanoma.18 It 
is plausible that advanced-stage disease and elevated 
mortality after a cancer diagnosis among PLWH are 
related to the biological effects of HIV-associated 
immunosuppression.
However, the more advanced-stage cancers and 
 elevated mortality reported among PLWH also could be 
related to receipt of suboptimal health care, a possibility 
supported by mounting data that PLWH are less likely to 
receive cancer treatment.19,20 Available data have not been 
able to disentangle these possibilities. To begin address-
ing this issue of suboptimal health care, we evaluated the 
association between HIV, cancer stage at presentation, 
and mortality after a cancer diagnosis after accounting 
for the type of treating health facility and reported indi-
vidual health insurance using data from >6 million US 
patients with cancer from the National Cancer Data Base 
(NCDB).
MATERIALS AND METHODS
The NCDB is a nationwide, hospital-based registry datab-
ase jointly sponsored by the American Cancer Society and 
the American College of Surgeons. Using the NCDB, 
we ascertained the following primary, malignant cancers 
 occurring in adults (those aged ≥18 years) between 2004 
and 2014: oral cavity, pharynx, and/or larynx (International 
Classification of Diseases for Oncology, 3rd Edition [ICD-O-3] 
topography codes C000-C009, C019-C069, C079-C099, 
C100-C109, C110-C119, C129-C140, C142, C148, and 
C320-C329); stomach (ICD-O-3 codes C160-C169); colo-
rectum (ICD-O-3 codes C180-C189, C199, and C209); 
anus (ICD-O-3 codes C210 and C218); liver (ICD-O-3 
code C220); pancreas (ICD-O-3 codes C250-C259); lung 
(ICD-O-3 codes C340-C349); female breast (ICD-O-3 
codes C500-C509); cervix (ICD-O-3 codes C530-C539); 
prostate (ICD-O-3 code C619); bladder (ICD-O-3 codes 
C670-C679); kidney (ICD-O-3 codes C649 and C659); 
and thyroid (ICD-O-3 code C739) and melanoma (ICD-
O-3 codes C440-C449 with histology codes 8720-8790). 
Cancers with the following histology codes were excluded: 
9050 to 9055, 9140, and 9590 to 9989. Patients with an 
unknown stage of disease, unknown date of diagnosis, or 
unknown last date of contact also were excluded.
The HIV status of each patient at the time of cancer 
diagnosis was defined using International Classification of 
Diseases, Ninth Revision (ICD-9) codes, with HIV posi-
tivity defined as the presence of codes 04200 to 04499, 
07953, or V08. Cancer stage at the time of presentation 
was defined as stages I, II, III, or IV using the collab-
orative staging algorithm from the sixth edition of the 
American Joint Committee on Cancer (AJCC) (https 
://cance rstag ing.org/cstag e/Pages/ defau lt.aspx). Factors 
related to health care were ascertained from the NCDB, 
including data regarding the type of health facility at 
which cancer care was administered (community center, 
comprehensive community center, teaching/research insti-
tution, National Cancer Institute network cancer center, 
integrated network, or other/unknown, as defined by the 
Commission on Cancer21) and the type of reported health 
insurance (private, Medicaid, Medicare, no insurance, or 
other government insurance). We hypothesized that the 
type of treating health facility reflects an important aspect 
of the quality of care received, whereas individual health 
insurance can influence a patient’s access to care.
Statistical Analysis
Polytomous logistic regression was used to estimate the 
association between HIV status and cancer stage at the 
time of presentation (with AJCC stage I as the referent 
group), adjusting for patient sex (male vs female), age 
(18-44 years, 45-54 years, 55-64 years, or ≥65 years), 
race (non-Hispanic white, black, Hispanic, other, or 
missing data), calendar year of cancer diagnosis (2004-
2006, 2007-2010, or 2011-2014), and median house-
hold income by zip code (<$38,000, $38,000-$47,999, 
$48,000-$62,999, ≥$63,000, or missing data). Analyses 
were conducted separately for each cancer site. P values 
for trend were calculated by fitting logistic regression 
models with stage categorized as an ordinal variable, 
 adjusting for the covariates listed above. To further assess 
whether any associations between HIV and cancer stage 
were attributable to factors related to suboptimal care, we 
adjusted for the type of health facility at which cancer 
treatment was received and the type of individual health 
insurance.
We next evaluated whether HIV was associated with 
overall mortality using Cox proportional hazards regres-
sion. Follow-up for each patient with cancer was calculated 
from the date of the cancer diagnosis to the date of death 
from any cause, with follow-up ending in 2014. Cases 
diagnosed between 2013 and 2014 were excluded to  ensure 
adequate follow-up time to ascertain mortality. These 
mortality analyses were limited to patients with stage I to 
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stage III disease due to the heterogeneity of disease bur-
den, treatment approaches, and outcomes that occur in 
patients with metastatic (stage IV) disease. Analyses were 
adjusted for age, sex, race, calendar year of cancer diag-
nosis, median household income, AJCC stage of disease, 
and cancer treatment (categorized as yes/no for receipt of 
surgery, radiotherapy, or chemotherapy). Additional mod-
els were adjusted for type of treating health facility and 
type of individual health insurance. The proportional 
hazards assumption was tested by examining parallelism 
in ln(-ln(survival)) versus ln(time) plots. No violations of 
this assumption were observed for HIV across any cancer 
site. However, violations were observed for cancer stage 
and treatment, requiring time-dependent adjustment for 
these 2 variables in regression models.
In a supplemental analysis, we examined logistic 
and Cox models for stage of disease and mortality out-
comes, respectively, within patient groups aged <65 years 
stratified by receipt of specific types of health insurance: 
1) private insurance; 2) Medicare; or 3) Medicaid.
RESULTS
We compared cancer stage at the time of presenta-
tion and mortality after cancer diagnosis in >6 million 
 patients with cancer in the United States from the NCDB, 
including 14,453 PLWH who were diagnosed with can-
cer between 2004 and 2014 (Table 1). HIV-infected 
 patients with cancer were younger, were more likely to be 
male and nonwhite, and had a lower median household 
 income compared with HIV-uninfected patients with can-
cer (P < .0001). The most common cancer diagnoses in 
PLWH were lung cancer (29.1% of all cases), colorectal 
cancer (14.1%), and prostate cancer (10.5%), compared 
with cancers of the breast (22.8%), prostate (17.8%), and 
lung (17.7%) among HIV-uninfected patients, reflecting 
differences in the patient sex distribution by HIV status. 
We observed significant differences in the percentage 
of uninsured patients with cancer by HIV status (HIV-
infected: 5.0% vs HIV-uninfected: 3.3%; P < .0001), 
with PLWH being approximately one-half as likely to 
report private health insurance (HIV-infected: 25.4% vs 
HIV-uninfected: 44.7%) and approximately 3 times more 
likely to be covered by Medicaid (HIV-infected: 17.9% vs 
HIV-uninfected: 5.9%). The likelihood of receiving cancer 
treatment and the type of health facility at which treatment 
was administered also differed by HIV status (P < .0001).
PLWH were more likely to be diagnosed with 
advanced-stage cancers of the oral cavity, liver, female 
breast, prostate, and thyroid and melanoma (P for trend 
<.05) (Table 2). After adjustment for both the type of 
treating health care facility and individual health insur-
ance, statistically significant trends toward later-stage 
disease remained, with the association between HIV 
and stage IV disease (vs stage I) ranging from 1.24 
(95% CI, 1.02-1.52) for liver cancer to 2.06 (95% CI, 
1.70-2.50) for female breast cancer. It is interesting to 
note that HIV was associated with a marginally earlier 
stage of disease at the time of diagnosis for colorectal 
cancer (stage IV vs stage I: odds ratio [OR], 0.89 [95% 
CI, 0.78-1.02; P for trend = .03]) and a substantially 
earlier stage for anal cancer (OR, 0.54 [95% CI, 0.41-
0.73; P for trend <.01]). After restricting analyses to 
patients aged <65 years and stratifying by receipt of 
either private insurance, Medicare, or Medicaid, results 
were largely consistent (see Supporting Table 1). The 
association between HIV and advanced-stage breast 
cancer was more pronounced among women with pri-
vate insurance (OR, 2.22) or Medicare (OR, 2.27), 
both of which are groups assumed to have good  access 
to care, compared with an OR of 0.77 in women 
with Medicaid. The association between HIV and 
 advanced-stage cancers of the stomach and kidney was 
not statistically significant overall but was strongly 
positive among patients with Medicare (stomach: OR, 
3.46 [95% CI, 1.67-7.48]; and kidney: 1.85 [95% CI, 
1.09-3.15]).
Among patients with stage I to stage III disease, 
HIV was found to be significantly associated with 
 elevated mortality after a cancer diagnosis for 13 of the 
14 sites evaluated, even after adjustment for stage at 
 diagnosis, first-course cancer treatment type of treating 
cancer facility, and type of individual health insurance 
(Table 3) (see Supporting Table 2). The strength of the 
association between HIV and overall mortality ranged 
from hazard ratios of 1.20 (95% CI, 1.14-1.26) for lung 
cancer to 1.85 (95% CI, 1.68-2.04), 1.85 (95% CI, 1.51-
2.27), and 2.93 (95% CI, 2.08-4.13), respectively, for 
cancers of the female breast, cervix, and thyroid. The 
5 cancers with the most pronounced HIV-associated 
elevations in mortality after diagnosis are illustrated in 
Figure 1 and included both virus-associated and non– 
virus-associated tumors. We also confirmed that PLWH 
experienced significantly elevated mortality even after 
including patients with metastatic (stage IV) disease (see 
Supporting Table 3).
DISCUSSION
The data from the current study regarding >6 million 
patients with cancer in the United States are consist-
ent with PLWH experiencing a more aggressive disease 
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course for cancer: herein, we reported significant associa-
tions between HIV and both advanced stage of disease 
at the time of presentation and elevated mortality after a 
cancer diagnosis. Specifically, PLWH were significantly 
more likely to be diagnosed with advanced-stage can-
cers of the oral cavity, liver, female breast, prostate, and 
TABLE 1. Characteristics of Patients in the NCDB (2004 Through 2014) According to HIV Status
Demographic Factors
Total
N = 6,382,579
No. (%)
HIV-Infected Patients
N = 14,453
No. (%)
HIV-Uninfected Patients
N = 6,368,126
No. (%) Chi-square P
Sex
Male 3,146,045 (49.3) 9296 (64.3) 3,136,749 (49.3) <.0001
Female 3,236,534 (50.7) 5157 (35.7) 3,231,377 (50.7)
Age at diagnosis, y
18-44 543,310 (8.5) 1452 (10) 541,858 (8.5) <.0001
45-54 1,075,558 (16.9) 3513 (24.3) 1,072,045 (16.8)
55-64 1,733,796 (27.2) 3597 (24.9) 1,730,199 (27.2)
≥65 3,029,915 (47.5) 5891 (40.8) 3,024,024 (47.5)
Race/ethnicity
White, non-Hispanic 4,726,015 (74.1) 7966 (55.1) 4,718,049 (74.1) <.0001
Black 328,450 (5.1) 1054 (7.3) 327,396 (5.1)
Hispanic 689,689 (10.8) 4533 (31.4) 685,156 (10.8)
Other 206,283 (3.2) 177 (1.2) 206,106 (3.2)
Missing data 432,142 (6.8) 723 (5) 431,419 (6.8)
Y of cancer diagnosis
2004-2006 1,628,351 (25.5) 5141 (35.6) 1,623,210 (25.5) <.0001
2007-2010 2,366,096 (37.1) 5912 (40.9) 2,360,184 (37.1)
2011-2014 2,388,132 (37.4) 3400 (23.5) 2,384,732 (37.4)
Median income level 
<$38,000 1,120,358 (17.6) 4150 (28.7) 1,116,208 (17.5) <.0001
$38,000-$47,999 1,466,892 (23) 3280 (22.7) 1,463,612 (23)
$48,000-$62,999 1,676,914 (26.3) 3254 (22.5) 1,673,660 (26.3)
≥$63,000 2,013,696 (31.5) 3444 (23.8) 2,010,252 (31.6)
Missing data 104,719 (1.6) 325 (2.3) 104,394 (1.6)
Cancer site
Oral cavity/pharynx/larynx 289,643 (4.5) 939 (6.5) 288,704 (4.5) <.0001
Stomach 106,060 (1.7) 290 (2) 105,770 (1.7)
Colorectum 784,001 (12.3) 2034 (14.1) 781,967 (12.3)
Anus 30,793 (0.5) 1052 (7.3) 29,741 (0.5)
Liver 107,544 (1.7) 823 (5.7) 106,721 (1.7)
Pancreas 211,219 (3.3) 498 (3.4) 210,721 (3.3)
Lung 1,130,306 (17.7) 4201 (29.1) 1,126,105 (17.7)
Melanoma 263,127 (4.1) 214 (1.5) 262,913 (4.1)
Female breast 1,449,954 (22.7) 1197 (8.3) 1,448,757 (22.8)
Cervix 95,222 (1.5) 330 (2.3) 94,892 (1.5)
Prostate 1,136,297 (17.8) 1513 (10.5) 1,134,784 (17.8)
Bladder 176,320 (2.8) 394 (2.7) 175,926 (2.8)
Kidney 314,810 (4.9) 708 (4.9) 314,102 (4.9)
Thyroid 287,283 (4.5) 260 (1.8) 287,023 (4.5)
Individual insurance status
Private 2,852,824 (44.7) 3667 (25.4) 2,849,157 (44.7) <.0001
Medicaid 380,678 (6.0) 2587 (17.9) 378,091 (5.9)
Medicare 2,770,671 (43.4) 7234 (50.0) 2,763,437 (43.5)
Uninsured 211,643 (3.3) 717 (5.0) 210,926 (3.3)
Government 34,223 (0.5) 72 (0.5) 34,151 (0.5)
Missing data 132,540 (2.1) 176 (1.2) 132,364 (2.1)
Type of treating health facility
Community center 628,450 (9.8) 1410 (9.8) 627,040 (9.8) <.0001
Comprehensive community center 2,712,165 (42.5) 5435 (37.6) 2,706,730 (42.5)
Teaching/research institution 1,466,395 (23) 3833 (26.5) 1,462,562 (23)
NCI network cancer center 731,239 (11.5) 1774 (12.3) 729,465 (11.5)
Integrated network 649,528 (10.2) 1463 (10.1) 648,065 (10.2)
Others/unknown 194,802 (3.1) 538 (3.7) 194,264 (3.1)
Receipt of surgery, radiotherapy or chemotherapy
Yes 5,758,785 (90.2) 11,598 (80.2) 5,747,187 (90.3) <.0001
No 610,101 (9.6) 2802 (19.4) 607,299 (9.5)
Unknown 13,693 (0.2) 53 (0.4) 13,640 (0.2)
Abbreviations: NCDB, National Cancer Data Base; NCI, National Cancer Institute.
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TABLE 2. ORs and 95% CIs Describing the Association Between Patient HIV Status and AJCC Stage  
of Disease at the Time of Diagnosis
Cancer Site
Total Cases
No. (%)
HIV-Infected Cases
No. (%)
HIV-Uninfected 
Cases
No. (%)
Model 1, Not 
Adjusted for Health 
Care Factorsa 
Model 2, Adjusted 
for Health Care 
Factorsb 
Oral cavity/pharynx/larynx
Stage I 65,128 (22.5) 127 (13.5) 65,001 (22.5) 1 1
Stage II 38,100 (13.2) 108 (11.5) 37,992 (13.2) 1.32 (1.02-1.71) 1.24 (0.96-1.6)
Stage III 50,123 (17.3) 176 (18.7) 49,947 (17.3) 1.52 (1.21-1.91) 1.38 (1.1-1.74)
Stage IV 136,292 (47.1) 528 (56.2) 135,764 (47.0) 1.54 (1.27-1.88) 1.35 (1.1-1.64)
P for trend .0001c .0134
Stomach
Stage I 28,157 (26.5) 76 (26.2) 28,081 (26.5) 1 1
Stage II 15,341 (14.5) 43 (14.8) 15,298 (14.5) 1.01 (0.69-1.47) 1.03 (0.71-1.5)
Stage III 15,783 (14.9) 39 (13.5) 15,744 (14.9) 0.83 (0.56-1.23) 0.85 (0.58-1.26)
Stage IV 46,779 (44.1) 132 (45.5) 46,647 (44.1) 0.95 (0.71-1.26) 0.94 (0.71-1.26)
P for trend .7826 .7070
Colorectum
Stage I 181,014 (23.1) 465 (22.9) 180,549 (23.1) 1 1
Stage II 208,371 (26.6) 616 (30.3) 207,755 (26.6) 1.16 (1.03-1.31) 1.13 (1-1.27)
Stage III 227,004 (29.0) 557 (27.4) 226,447 (29.0) 1 (0.88-1.13) 0.98 (0.87-1.11)
Stage IV 167,612 (21.4) 396 (19.5) 167,216 (21.4) 0.94 (0.82-1.08) 0.89 (0.78-1.02)
P for trend .1559 .0313
Anus
Stage I 6130 (19.9) 229 (21.8) 5901 (19.8) 1 1
Stage II 11,996 (39.0) 385 (36.6) 11,611 (39.0) 0.86 (0.72-1.02) 0.83 (0.7-0.99)
Stage III 10,064 (32.7) 369 (35.1) 9695 (32.6) 0.9 (0.76-1.08) 0.86 (0.72-1.03)
Stage IV 2603 (8.5) 69 (6.6) 2534 (8.5) 0.57 (0.43-0.76) 0.54 (0.41-0.73)
P for trend .0100 .0027
Liver
Stage I 38,333 (35.6) 242 (29.4) 38,091 (35.7) 1 1
Stage II 21,727 (20.2) 165 (20.0) 21,562 (20.2) 1.1 (0.9-1.35) 1.09 (0.89-1.33)
Stage III 27,884 (25.9) 246 (29.9) 27,638 (25.9) 1.27 (1.06-1.52) 1.31 (1.09-1.57)
Stage IV 19,600 (18.2) 170 (20.7) 19,430 (18.2) 1.19 (0.97-1.45) 1.24 (1.02-1.52)
P for trend .0309 .0084
Pancreas
Stage I 17,995 (8.5) 46 (9.2) 17,949 (8.5) 1 1
Stage II 62,661 (29.7) 142 (28.5) 62,519 (29.7) 0.84 (0.6-1.17) 0.84 (0.6-1.17)
Stage III 22,989 (10.9) 45 (9.0) 22,944 (10.9) 0.65 (0.43-0.99) 0.65 (0.43-0.98)
Stage IV 107,574 (50.9) 265 (53.2) 107,309 (50.9) 0.83 (0.6-1.13) 0.82 (0.6-1.13)
P for trend .5813 .5703
Lung
Stage I 238,623 (21.1) 790 (18.8) 237,833 (21.1) 1 1
Stage II 63,768 (5.6) 224 (5.3) 63,544 (5.6) 0.91 (0.79-1.06) 0.92 (0.79-1.07)
Stage III 293,173 (25.9) 1090 (25.9) 292,083 (25.9) 0.94 (0.85-1.03) 0.93 (0.84-1.01)
Stage IV 534,742 (47.3) 2097 (49.9) 532,645 (47.3) 0.97 (0.89-1.05) 0.97 (0.89-1.05)
P for trend .8945 .9718
Melanoma
Stage I 172,448 (65.5) 110 (51.4) 172,338 (65.5) 1 1
Stage II 42,586 (16.2) 35 (16.4) 42,551 (16.2) 1.12 (0.77-1.65) 1.05 (0.71-1.54)
Stage III 32,356 (12.3) 38 (17.8) 32,318 (12.3) 1.52 (1.05-2.21) 1.41 (0.97-2.06)
Stage IV 15,737 (6.0) 31 (14.5) 15,706 (6.0) 2.37 (1.58-3.56) 1.96 (1.3-2.97)
P for trend <.0001 .0022
Female breast
Stage I 692,293 (47.8) 453 (37.8) 691,840 (47.8) 1 1
Stage II 502,964 (34.7) 419 (35) 502,545 (34.7) 1.2 (1.05-1.37) 1.16 (1.02-1.33)
Stage III 179,480 (12.4) 185 (15.5) 179,295 (12.4) 1.36 (1.14-1.62) 1.26 (1.06-1.5)
Stage IV 75,217 (5.2) 140 (11.7) 75,077 (5.2) 2.36 (1.95-2.85) 2.06 (1.70-2.50)
P for trend <.0001 <.0001
Cervix
Stage I 45,105 (47.4) 146 (44.2) 44,959 (47.4) 1 1
Stage II 14,506 (15.2) 53 (16.1) 14,453 (15.2) 1.2 (0.87-1.65) 1.05 (0.76-1.45)
Stage III 22,528 (23.7) 78 (23.6) 22,450 (23.7) 1.05 (0.79-1.38) 0.92 (0.69-1.22)
Stage IV 13,083 (13.7) 53 (16.1) 13,030 (13.7) 1.42 (1.03-1.96) 1.22 (0.88-1.69)
P for trend .0866 .5754
Prostate
Stage I/IId 939,405 (82.7) 1190 (78.7) 938,215 (82.7) 1 1
Stage III 115,700 (10.2) 135 (8.9) 115,565 (10.2) 0.97 (0.82-1.17) 0.96 (0.8-1.15)
Stage IV 81,192 (7.1) 188 (12.4) 81,004 (7.1) 1.81 (1.55-2.12) 1.57 (1.34-1.83)
P for trend <.0001 <.0001
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thyroid and melanoma. Furthermore, HIV was associ-
ated with elevated mortality after a cancer diagnosis for 
13 of the 14 cancer sites evaluated, including an almost 
doubling and tripling of mortality for female breast and 
thyroid cancers, respectively. The persistence of these 
 associations after adjustment for factors related to the 
 receipt of health care provides support for a biological 
link between HIV-related immunosuppression and can-
cer progression.
To the best of our knowledge, only 1 prior study to 
date broadly examined cancer stage in PLWH; in that 
study, HIV was found to be associated with a more ad-
vanced stage of disease in patients with cancers of the 
lung, breast, prostate, and bladder and melanoma.17 
However, that study did not have information regarding 
the type of care received by HIV status.17 To mitigate 
this fact, the authors compared their results with those 
observed among recipients of solid organ transplants, an 
immunosuppressed patient group that, unlike PLWH, 
has increased use of health care. Consistent results for 
more advanced-stage diagnoses of bladder cancer and 
melanoma suggested a possible biological role for immu-
nosuppression in the progression of these cancers. We be-
lieve the current study was unique in that the availability 
of health insurance information in the NCDB enabled 
us to more directly address potential nonbiological ex-
planations for later-stage cancer diagnoses in PLWH. 
We confirmed prior associations between HIV and lat-
er-stage breast cancer, prostate cancer, and melanoma.17 
In addition, herein we reported associations between 
HIV and advanced-stage cancers of the oral cavity, liver, 
and thyroid. Because these associations were indepen-
dent of the type of health insurance a patient reported, it 
appears that access to health care is not the sole explana-
tion for the stage shifts.
The results of the current study do highlight one no-
table exception: PLWH were substantially more likely to 
be diagnosed with less advanced anal cancers compared 
with their HIV-uninfected counterparts. This potentially 
represents an example of increased health care being di-
rected toward the HIV-infected population, a distinct 
possibility given the ongoing targeting of anal cancer 
screening procedures to HIV-infected men who have sex 
with men.22 It is important to note that although these 
immunosuppressed patients were more likely to be di-
agnosed with less advanced disease, their stage-adjusted 
mortality was higher than that of HIV-uninfected pa-
tients. Mortality after an anal cancer diagnosis was found 
to be approximately 34% higher in PLWH compared 
with HIV-uninfected patients diagnosed with the same 
stage of disease in the current study.
The association between HIV and elevated mor-
tality after a cancer diagnosis was observed for pa-
tients with stage I to stage III tumors regardless of 
Cancer Site
Total Cases
No. (%)
HIV-Infected Cases
No. (%)
HIV-Uninfected 
Cases
No. (%)
Model 1, Not 
Adjusted for Health 
Care Factorsa 
Model 2, Adjusted 
for Health Care 
Factorsb 
Bladder
Stage I 81,514 (46.2) 170 (43.1) 81,344 (46.2) 1 1
Stage II 46,726 (26.5) 118 (30) 46,608 (26.5) 1.2 (0.95-1.52) 1.19 (0.94-1.5)
Stage III 18,135 (10.3) 36 (9.1) 18,099 (10.3) 0.9 (0.63-1.29) 0.89 (0.62-1.28)
Stage IV 29,945 (17.0) 70 (17.8) 29,875 (17.0) 1.04 (0.78-1.38) 1 (0.75-1.33)
P for trend .7419 .8901
Kidney
Stage I 185,725 (59.0) 412 (58.2) 185,313 (59.0) 1 1
Stage II 28,666 (9.1) 56 (7.9) 28,610 (9.1) 0.81 (0.61-1.08) 0.84 (0.64-1.11)
Stage III 46,784 (14.9) 105 (14.8) 46,679 (14.9) 1.05 (0.85-1.31) 1.07 (0.86-1.33)
Stage IV 53,635 (17.0) 135 (19.1) 53,500 (17.0) 1.09 (0.89-1.32) 1.06 (0.87-1.3)
P for trend .6677 .6752
Thyroid
Stage I 207,173 (72.1) 149 (57.3) 207,024 (72.1) 1 1
Stage II 23,217 (8.1) 23 (8.8) 23,194 (8.1) 0.94 (0.59-1.48) 0.92 (0.58-1.45)
Stage III 35,457 (12.3) 42 (16.2) 35,415 (12.3) 1.23 (0.85-1.78) 1.15 (0.8-1.67)
Stage IV 21,436 (7.5) 46 (17.7) 21,390 (7.5) 1.95 (1.36-2.81) 1.67 (1.16-2.41)
P for trend .0007 .0072
Abbreviations: AJCC, American Joint Committee on Cancer; OR, odds ratio.
aModel 1 was adjusted for age, sex, race, calendar year of cancer diagnosis, and median household income (by zip code).
bModel 2 was adjusted for age, sex, race, calendar year of cancer diagnosis, median household income (by zip code), patient-reported individual health insur-
ance, and type of treating cancer facility.
cBold text indicates statistical significance for the P for trend test describing the likelihood of diagnosis with more advanced stages of disease by HIV status.
dIndividual AJCC stage groupings with <10 patients were collapsed into categories to provide more stable effect estimates (eg, patients with stage I and stage II 
prostate cancer were combined into stage I/II disease).
TABLE 2. Continued
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their initiating etiology. Elevations in mortality among 
 patients with cancer ranged from 20% (lung cancer) 
to approximately 3-fold (thyroid cancer) in PLWH, 
with the largest HIV-related differences observed for 
cancers with a generally good prognosis (eg, breast and 
thyroid cancers).23 These data are consistent with prior 
work demonstrating higher mortality rates among pa-
tients with cancer within the setting of HIV.18,24-26 
However, this study not only accounted for clinically 
important prognostic factors such as cancer stage and 
treatment, but also demonstrated higher mortality in 
HIV-infected patients with cancer after accounting for 
the type of treating health facility (quality of cancer 
care) and individual health insurance (access to care). 
Furthermore, the NCDB includes only patients with 
cancer who at least initiated cancer care, as opposed 
to our prior study that included diagnoses of cancer 
among all PLWH, regardless of health care use.18
Ultimately, patients with cancer with the same stage 
of disease at the time of presentation, the same initial treat-
ment modality, reporting similar health insurance, and re-
ceiving cancer care at the same type of health care facility 
still died more often if they were infected with HIV at the 
time of their cancer diagnosis. A biological explanation 
TABLE 3. HRs and 95% CIs Describing the Association Between Patient HIV Status and Mortality After 
Cancer Diagnosis
Cancer Site Total Cases Deaths (% of Cases)
Model 1, Not Adjusted for Health 
Care Factorsa 
Model 2, Adjusted for Health 
Care Factorsb 
Oral cavity/pharynx/larynx
HIV-infected 353 194 (55.0%) 1.89 (1.64-2.18) 1.66 (1.44-1.92)
HIV-uninfected 123,760 44,303 (35.8%) 1 1
Stomach
HIV-infected 141 106 (75.2%) 1.25 (1.03-1.52) 1.20 (0.98-1.45)
HIV-uninfected 47,263 28,895 (61.1%) 1 1
Colorectum
HIV-infected 1524 903 (59.3%) 1.65 (1.54-1.76) 1.58 (1.48-1.69)
HIV-uninfected 505,650 181,240 (35.8%) 1 1
Anus
HIV-infected 764 319 (41.8%) 1.56 (1.38-1.76) 1.34 (1.19-1.52)
HIV-uninfected 21,032 6601 (31.4%) 1 1
Liver
HIV-infected 515 422 (81.9%) 1.32 (1.19-1.46) 1.29 (1.16-1.42)
HIV-uninfected 65,652 46,977 (71.6%) 1 1
Pancreas
HIV-infected 212 198 (93.4%) 1.37 (1.19-1.59) 1.34 (1.16-1.54)
HIV-uninfected 81,115 67,982 (83.8%) 1 1
Lung
HIV-infected 1908 1547 (81.1%) 1.24 (1.18-1.3) 1.20 (1.14-1.26)
HIV-uninfected 483,000 340,444 (70.5%) 1 1
Melanoma
HIV-infected 145 57 (39.3%) 1.79 (1.38-2.32) 1.65 (1.27-2.14)
HIV-uninfected 194,402 37,221 (19.1%) 1 1
Female breast
HIV-infected 957 399 (41.7%) 1.98 (1.80-2.19) 1.85 (1.68-2.04)
HIV-uninfected 1,099,101 173,881 (15.8%) 1 1
Cervix
HIV-infected 218 95 (43.6%) 2.06 (1.68-2.52) 1.85 (1.51-2.27)
HIV-uninfected 67,181 17,506 (26.1%) 1 1
Prostate
HIV-infected 1170 236 (20.2%) 1.65 (1.46-1.88) 1.56 (1.37-1.77)
HIV-uninfected 901,852 112,889 (12.5%) 1 1
Bladder
HIV-infected 302 217 (71.9%) 1.71 (1.50-1.96) 1.66 (1.45-1.9)
HIV-uninfected 117,311 57,533 (49.0%) 1 1
Kidney
HIV-infected 514 204 (39.7%) 1.52 (1.32-1.75) 1.41 (1.22-1.62)
HIV-uninfected 205,898 45,884 (22.3%) 1 1
Thyroid
HIV-infected 190 33 (17.4%) 3.10 (2.20-4.37) 2.93 (2.08-4.13)
HIV-uninfected 206,656 7841 (3.8%) 1 1
Abbreviation: HR, hazard ratio.
aModel 1 was adjusted for age, sex, race, calendar year of cancer diagnosis, median household income (by zip code), American Joint Committee on Cancer 
stage of disease, and treatment.
bModel 2 was adjusted for model 1 plus the type of individual health insurance and treating cancer facility.
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for this persistent effect of immunosuppression on out-
comes in patients with cancer is plausible when considered 
alongside data suggesting that immunosuppressed solid 
organ transplant recipients also experience elevated mor-
tality after a cancer diagnosis,27 recent advances in cancer 
survival associated with immune-boosting therapies,28-30 
and data suggesting that additional cancer-specific out-
comes (ie, disease recurrence after successful first-course 
treatment) are poorer in the presence of HIV.31 However, 
it must be acknowledged that this evaluation focused on 
overall mortality as the clinically relevant outcome rather 
than death due specifically to cancer. It is possible that 
PLWH in the current study died more often due in part 
to a higher risk of additional causes of death, including 
AIDS and other HIV-associated comorbidities.
The current study is notable not only for the size 
and national scope of the NCDB but also because to the 
best of our knowledge prior studies have not been able to 
broadly examine the possibility that variations in health 
care could offer a nonbiological explanation for the more 
advanced-stage cancer and elevated mortality after a can-
cer diagnosis noted among PLWH. Instead of proving a 
nonbiological explanation for the link between HIV and 
tumor aggressiveness, our data suggest that biology could 
underlie this association.
Certain limitations of the current study should be 
noted. First, we were unable to rule out the possibility of 
HIV-related differences in access to health care that we 
were not able to account for in our models. For example, 
our classification of insurance into large groupings (eg, 
private insurance) may have failed to adequately adjust 
for variations according to insurance provider or coverage 
levels. Simple adjustment for receipt of health insurance 
also likely did not capture variations in the use of health 
services (ie, having and using insurance are not equiva-
lent). Additional misclassification also may have existed 
for our exposure; hospital discharge diagnoses likely un-
derascertain HIV status. As noted above, our evaluation 
of overall mortality after a cancer diagnosis was not able 
to capture potentially important HIV-related differences 
in cancer-specific mortality. Finally, we were not able 
to address the association between clinical measures of 
 immunosuppression (eg, CD4 count) or HIV treatment 
(eg, antiretroviral therapy) and outcomes because the 
NCDB does not collect this information. Future studies 
that include clinical HIV data should evaluate these more 
refined metrics of patient immune status.
The results of the current study of >6 million pa-
tients with cancer in the United States demonstrated 
that those infected with HIV were more likely to be 
diagnosed with advanced-stage cancers of the oral 
cavity, liver, female breast, prostate, and thyroid and 
melanoma. PLWH who were diagnosed with stage I 
to stage III cancer also experienced elevated mortal-
ity after diagnosis across a range of tumor etiologies. 
These associations persisted even after accounting for 
HIV-related differences with regard to the type of 
treating cancer facility and patient-reported individual 
health insurance. Although the possibility remains that 
the current study findings could be explained partly by 
unmeasured differences in health care use, differences 
in applied cancer treatment, or mortality from noncan-
cer comorbidities, the results support a possible biolog-
ical association between HIV and tumor behavior.
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Figure 1. Hazard ratios (HRs) illustrating the association bet-
ween HIV status and elevated mortality after a cancer diagnosis 
for the 5 cancer sites with the strongest effect estimates, 
according to the type of individual health insurance reported. 
(Triangle indicates original HR estimate; circle, estimate for 
those with private insurance; square, estimate for those with 
Medicaid; diamond, estimate for those with Medicare). *Oral 
cavity includes the oral cavity, pharynx, and/or larynx.
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